Merck & Co., Inc 8-K, filed Aug 20, 2021
Merck & Co., Inc. (MRK)
8-K
2021-08-20
For: 2021-08-19
View Original
Added on
April 02, 2026
About this 8-K
Merck & Co., Inc filed this 8-K on August 20, 2021, reporting on events of August 19, 2021.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| Date of Report (Date of earliest event reported) | August 20, 2021 |
( |
|
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number) |
(IRS Employer Identification No.) |
|
, ,
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
| Registrant’s telephone number, including area code |
(
|
|
Not Applicable
|
|
(Former name or former address, if changed since last report)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b–2 of the Securities Exchange
Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
|
Title of Each Class
|
Trading
Symbol(s)
|
Name of Each Exchange
on which Registered
|
||
|
|
||||
|
|
||||
|
|
||||
| Item 5.02 – |
Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
(b) Incorporated by reference is a press release issued by Merck & Co., Inc. (the “Company”) on August 20, 2021, attached as Exhibit 99.1,
announcing the resignation of Leslie A. Brun from the Company’s Board of Directors effective August 19, 2021.
| Item 9.01 – |
Financial Statements and Exhibits.
|
|
(d)
|
Exhibits:
|
|
Exhibit Number
|
|
Description
|
|
99.1
|
|
Press Release issued August 20, 2021.
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Merck & Co., Inc.
|
|||
|
Date: August 20, 2021
|
By:
|
/s/ Kelly E. W. Grez
|
|
|
Name:
|
Kelly E. W. Grez | ||
|
Title:
|
Deputy Corporate Secretary | ||
3
EXHIBIT INDEX
|
Exhibit No.
|
Description of Exhibit |
| Press Release issued August 20, 2021. |
Exhibit 99.1
![]() |
News Release |
FOR IMMEDIATE RELEASE
|
Media Contacts:
|
Patrick Ryan
|
Investor Contacts:
|
Peter Dannenbaum
|
|
(973) 275-7075
|
(908) 740-1037
|
||
|
Melissa Moody
(215) 407-3536
|
Raychel Kruper
(908) 740-2107
|
Leslie A. Brun Resigns from Merck Board of Directors
KENILWORTH, N.J., Aug. 20, 2021 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Leslie A. Brun, its
independent lead director, has resigned from its Board of Directors, effective August 19, 2021. Mr. Brun is stepping down due to his decision to become chairman and chief executive officer of Ariel Alternatives, LLC, a subsidiary of Ariel
Investments, LLC, a private equity initiative being created to help scale minority-owned businesses to serve as tier 1 suppliers to Fortune 500 companies. Merck is currently evaluating making an investment with Ariel Alternatives.
“Les has been an invaluable member of Merck’s board for many years and we have benefitted greatly from his leadership, wise
counsel and friendship,” said Rob Davis, chief executive officer and president, Merck. “While we will miss him, we recognize the importance of the task Les is undertaking at Ariel Alternatives, and we wish him great success.”
The company intends to name a new independent lead director in the near future.
About Merck
For 130 years, Merck, known as MSD outside of the
United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and
population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including
cancer, infectious diseases such as HIV and Ebola and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the
meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and
uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and
internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s
ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for
innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the
company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
# # #
Page 2
